Blar i forfatter "Kileng, Hege"

Viser treff 1-8 av 8

    • Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals 

      Howe, Anita Y.M.; Rodrigo, Chaturaka; Cunningham, Evan B.; Douglas, Mark W.; Dietz, Julia; Grebely, Jason; Popping, Stephanie; Sfalcin, Javier Alejandro; Parczewski, Milosz; Sarrazin, Christoph; de Salazar, Adolfo; Fuentes, Ana; Sayan, Murat; Quer, Josep; Kjellin, Midori; Kileng, Hege; Mor, Orna; Lennerstrand, Johan; Fourati, Slim; Di Maio, Velia Chiara; Chulanov, Vladimir; Pawlotsky, Jean-Michel; Harrigan, P. Richard; Ceccherini-Silberstein, Francesca; Garcia, Federico (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-02-24)
      Background & Aims: Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients with chronic HCV infection. However, in some patients in whom therapy fails, resistance-associated substitutions (RASs) can develop, limiting retreatment options and risking onward resistant virus transmission. In this study, we evaluated RAS prevalence and distribution, including novel NS5A RASs and ...

    • Chronic hepatitis C: Epidemiology, viral resistance, and public health implications 

      Kileng, Hege (Doctoral thesis; Doktorgradsavhandling, 2019-06-14)
      Chronic hepatitis C: Epidemiology, viral resistance, and public health implications Chronic hepatitis C virus (HCV) infection can progress to cirrhosis and end-stage liver disease. The infection is frequently asymptomatic, leaving many infected individuals unaware of the diagnosis until complications occur. The total number of HCV infections is projected to remain stable or to decline, but the ...

    • Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway 

      Kjellin, Midori; Kileng, Hege; Akaberi, Dario; Palanisamy, Navaneethan; Duberg, Ann-Sofi; Danielsson, Astrid; Kristiansen, Magnhild Gangsøy; Nöjd, Johan Edvin; Aleman, Soo; Gutteberg, Tore Jarl; Goll, Rasmus; Lannergård, Anders; Lennerstrand, Johan (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-08-19)
      <i>Background</i>: The NS5A resistance-associated substitution (RAS) Y93H is found quite frequently (5–10%) at baseline in direct-acting antiviral agents (DAA) treatment-naïve genotype (GT) 3a patients when studied by the population-sequencing method (cut-off 20%). This RAS may impair HCV DAA treatment response, since it possesses a high fold <i>in vitro</i> resistance to daclatasvir (DCV) and ...

    • Future complications of chronic hepatitis C in a low-risk area: Projections from the hepatitis c study in Northern Norway 

      Kileng, Hege; Bernfort, Lars; Gutteberg, Tore Jarl; Moen, Odd Sverre; Kristiansen, Magnhild Gangsøy; Paulssen, Eyvind Jakob; Berg, Leif Kyrre; Florholmen, Jon; Goll, Rasmus (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-09-16)
      <i>Background</i>: Hepatitis C (HCV) infection causes an asymptomatic chronic hepatitis in most affected individuals, which often remains undetected until cirrhosis and cirrhosis-related complications occur. Screening of high-risk subjects in Northern Norway has revealed a relatively low prevalence in the general population (0.24%). Despite this, late complications of HCV infection are increasing. ...

    • Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy 

      Kileng, Hege; Kjellin, Midori; Akaberi, Dario; Bergfors, Assar; Duberg, Ann-Sofi; Wesslen, Lars; Danielsson, Astrid; Kristiansen, Magnhild Gangsøy; Gutteberg, Tore Jarl; Goll, Rasmus; Lannergård, Anders; Lennerstrand, Johan (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-05)
      <i>Objectives</i>: Resistance-associated substitutions (RASs) may impair treatment response to direct-acting antivirals (DAA) in hepatitis C virus (HCV) treatment. We investigated the effects of baseline NS3-RASs (Q80K and R155K) and clinically relevant NS5A-RASs in patients with HCV genotype (GT) 1a infection on treatment outcome, with or without resistance-based DAA-treatment. This multi-center ...

    • Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease 

      Goll, Rasmus; Moe, Øystein Kittel; Johnsen, Kay-Martin; Meyer, Renate Weenås; Friestad, Joachim; Gundersen, Mona Dixon; Kileng, Hege; Johnsen, Knut; Florholmen, Jon (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-17)
      Background and aims - Biological therapy for inflammatory bowel disease is efficient in many cases but not all. The underlying molecular mechanisms behind non-response to biological therapy in inflammatory bowel disease are poorly described. Therefore, we aimed to characterize the mucosal cytokine transcript profile in non-immunogenic, non-responder patients with adequate trough level.<p> <p>Material ...

    • Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study 

      Johnsen, Kay-Martin; Florholmen, Jon; Moe, Øystein Kittel; Gundersen, Mona Dixon; Beilfuss, Julia; Kileng, Hege; Sørbye, Sveinung; Goll, Rasmus (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-16)
      Background - The long-term outcomes of Ulcerative colitis (UC) after discontinuation of biological therapy are largely unknown. There is also a lack of accurate and validated markers that can predict outcome after withdrawal accurately. The aims of this study were to describe the long-term outcomes in UC patients following cessation of anti-TNF therapy and explore potential biomarkers as an approach ...

    • Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study 

      Kileng, Hege; Gutteberg, Tore Jarl; Goll, Rasmus; Paulssen, Eyvind Jakob (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-02-26)
      <i>Background - </i>Chronic hepatitis C virus (HCV) infection can progress to cirrhosis and end-stage liver disease in a substantial proportion of patients. The infection is frequently asymptomatic, leaving many infected individuals unaware of the diagnosis until complications occur. This advocates the screening of healthy individuals. The aim of this study was to estimate the prevalence of HCV ...